Literature DB >> 26029600

Pulmonary capillary haemangiomatosis - An unusual cause of hypoxia.

Kerry Aston1, Gareth J Riddell1, Mary N Sheppard2, Athol U Wells2, Marshall S Riley1.   

Abstract

We describe the case of a 58-year-old man who presented with progressive dyspnoea on exertion and severe exertional hypoxia. There was a paucity of radiological findings, mild pulmonary hypertension, and no demonstrable anatomical shunt. Post mortem examination of lung tissue suggested a diagnosis of pulmonary capillary haemangiomatosis. The case is unusual in displaying few radiological findings. We postulate that the severe hypoxia was due to shunting through the abnormal capillary proliferations.

Entities:  

Keywords:  Exercise; Hypoxia; Pulmonary capillary haemangiomatosis; Pulmonary hypertension

Year:  2012        PMID: 26029600      PMCID: PMC3920353          DOI: 10.1016/j.rmcr.2012.09.001

Source DB:  PubMed          Journal:  Respir Med Case Rep        ISSN: 2213-0071


Case report

A 58-year-old man presented with a 2-year history of progressive exertional dyspnoea. He had smoked 30 cigarettes daily, but had ceased smoking 10 years before presentation. There was a history of systemic hypertension treated with an angiotensin converting enzyme inhibitor. There was no other medical history of note and in particular no history of chronic liver disease or hereditary haemorrhagic telangiectasia. Physical examination was unremarkable with no signs of cardiac defeat, no cardiac murmurs and no adventitial sounds on auscultation of the chest. Chest X-ray showed no abnormality. Spirometry showed an FEV1 of 3.52 l (110% predicted), and an FVC of 4.36 l (105% predicted), (FEV1/FVC 81%). Carbon monoxide diffusing capacity was 49% predicted. High resolution CT scans showed no significant lung parenchymal abnormality. A CT pulmonary angiogram showed no thromboembolic disease. An isotope ventilation perfusion scan was unremarkable. A cardiopulmonary exercise test showed slightly reduced exercise tolerance with maximum oxygen consumption of 23.2 ml kg−1 min−1 (81% predicted). The exercise test also showed marked desaturation measured by pulse oximetry (95% at rest to 77% at peak exercise), low end-tidal partial pressure of carbon dioxide (maximum value of 32 mmHg) and high ventilatory equivalent for CO2 (nadir value of 39), all suggesting ventilation perfusion mismatch or shunt. Contrast echocardiography showed no intra cardiac shunt and otherwise normal appearances. Cardiac catheterisation showed a mean right atrial pressure of 5 mmHg, a mild increase in pulmonary artery pressure with mean of 26 mmHg, normal pulmonary capillary wedge pressure of 10 mmHg, cardiac output of 4.7 l min−1, and cardiac index of 4.13 l min−1 m−2. Pulmonary vascular resistance was slightly elevated at 3.4 Wood Units. He continued to deteriorate symptomatically. Twelve months later, spirometry was unchanged but transfer factor was 38% predicted. Arterial blood sampling breathing room air at rest showed paO2 of 56 and paCO2 of 34 mmHg. After 30 min breathing 98% O2, the values were 128 and 34 mmHg respectively, giving a calculated shunt of approximately 27%. A microaggregate study showed no intrapulmonary shunt. Repeat echocardiography showed normal left and right ventricular appearances and function. There was mild tricuspid regurgitation with an estimated right ventricular systolic pressure of 30 mmHg by Doppler. Magnetic resonance imaging of the heart was normal. Repeat high-resolution CT scan showed the impression of very subtle diffuse nodular opacities. Open lung biopsy showed scanty small foci of interstitial fibrosis, but no widespread pulmonary fibrosis. There were focal areas of capillary congestion within lobules, but no actual double layer of capillaries, or extension of capillaries into the interstitium, interlobular septa or bronchioles. Haemosiderin laden macrophages were prominent in alveolar spaces. Occasional small veins showed evidence of sclerosis, but there was no definite occlusion of veins and these changes were felt to be insufficient to make a diagnosis of pulmonary veno-occlusive disease (PVOD). There were some regions of increased cellularity in the alveolar walls, reminiscent of pulmonary capillary haemangiomatosis (PCH), but again, insufficient to confirm this diagnosis. Overall, there was some suspicion of PVOD or PCH from the biopsy, but the changes were subtle and felt to be non-diagnostic. A vasculitic process was also considered possible. Warfarin and long-term oxygen therapy were commenced. On the basis that a vasculitic process was possible, a trial of methylprednisolone and pulsed cyclophosphamide was started. However, further deterioration occurred and he died approximately 3 years after initial presentation. Post mortem examination of the heart and lungs was performed. There was biventricular hypertrophy. Sections of the heart demonstrated intraventricular septal hypertrophy with thickness of 20–22 mm. The circumferential thickness of the left ventricle was 16 mm (normal 13–15 mm). Right ventricular thickness was 6 mm (normal 3–5 mm). Histology of the lungs showed mild pulmonary arterial medial hypertrophy and congestion in the lower lobes. There were multiple focal capillary proliferations within alveolar and bronchiolar walls throughout all areas examined (Fig. 1). There was associated fresh haemorrhage but little evidence of old haemorrhage. Venous occlusive lesions were not identified. The capillary proliferations were felt to be sufficient to diagnose PCH.
Fig. 1

a) Low power of the lung with expansion by multiple interlacing capillary channels filled with red blood cells. Haematoxylin and eosin ×200 magnification. b) Higher power of the lung with expansion by multiple interlacing capillary channels filled with red blood cells. Haematoxylin and eosin ×400 magnification. c) Lung section showing immunostaining with CD31. Several capillary layers/channels are visible within the lung interstitium.

PCH was first described by Wagenvoort in 1978. It is a rare disorder of alveolar capillary proliferation and presents with features similar to idiopathic pulmonary hypertension or PVOD. There are fewer than 40 reported cases. The typical patient is aged 20–40 years and there is an equal sex incidence. Prognosis is poor and median survival is 3 years, with a typical clinical course of progressive, unrelenting symptoms of pulmonary hypertension. The hallmark of histology is proliferation of small capillaries within the interstitium and alveolar walls. One report suggested considerable overlap histologically between PVOD and PCH with features of PCH present in cases of PVOD and vice versa. Common clinical features of PCH are dyspnoea and right heart failure. Haemoptysis, pleural effusion and acropachy occur less commonly. Clinically, PCH is difficult to distinguish from PVOD. Progressive dyspnoea and fatigue are common to both. Haemoptysis and haemorrhagic pleural effusions occur in 30% of PCH but not with PVOD. Our case was unusual in the paucity of radiological abnormalities. Only when the disease was very advanced did very subtle CT abnormalities become evident. Characteristic CT findings in PCH include diffuse bilateral thickening of the interlobular septae and small centrilobular, poorly circumscribed nodular opacities. Septal lines are present in both PCH and PVOD, but are more numerous in PVOD than PCH. Conversely, the presence of visible, better circumscribed ground glass opacities is more suggestive of PCH than PVOD. Hypoxia is not uncommon in PCH. In our patient, the cardiopulmonary exercise test and the high FiO2 study were physiologically in keeping with significant right to left shunt, but no shunt could be identified anatomically. A patent foramen ovale is unlikely to have been responsible as pulmonary hypertension was mild. We postulate that a small-vessel intrapulmonary shunt was responsible, with shunting occurring through the capillary proliferation present as part of the disease. In PCH elevated pulmonary arterial pressures and normal/low pulmonary capillary wedge pressures are seen. Pulmonary hypertension was unusually mild in our case, and it is possible that shunting through capillary channels resulted in relatively low pulmonary vascular resistance and pulmonary arterial pressures. The diagnosis in our patient was not made ante-mortem, and empirical therapy proved futile. There are no randomised controlled trials to provide evidence for the safety and efficacy of pharmacological agents to treat PCH. The use of steroids and cyclophosphamide has proved ineffective in several cases, although one case of PCH with atypical endotheliomatosis was successfully treated with doxycycline. In contrast to idiopathic pulmonary arterial hypertension, in which epoprostenol therapy is effective, prostanoids show deleterious effects in PCH. In summary, we present a case of PCH showing no diagnostic radiological features despite otherwise severe disease. Our case illustrates the diagnostic and therapeutic difficulties associated with PCH.

Conflict of interest statement

None of the authors has any conflict of interest to declare.
  10 in total

1.  Images in cardiovascular medicine. Pulmonary capillary hemangiomatosis.

Authors:  Shyam S Kothari; Priya Jagia; Ashish Gupta; Navreet Singh; Ruma Ray
Journal:  Circulation       Date:  2009-07-28       Impact factor: 29.690

2.  Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases.

Authors:  Sylvie Lantuéjoul; Mary N Sheppard; Bryan Corrin; Margaret M Burke; Andrew G Nicholson
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

3.  High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease.

Authors:  B Dufour; S Maître; M Humbert; F Capron; G Simonneau; D Musset
Journal:  AJR Am J Roentgenol       Date:  1998-11       Impact factor: 3.959

4.  Pulmonary capillary hemangiomatosis as cause of pulmonary hypertension in a young woman with systemic lupus erythematosus.

Authors:  J Fernández-Alonso; T Zulueta; J R Reyes-Ramirez; M J Castillo-Palma; J Sanchez-Román
Journal:  J Rheumatol       Date:  1999-01       Impact factor: 4.666

Review 5.  From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.

Authors:  Aletta Ann Frazier; Teri J Franks; Tan-Lucien H Mohammed; Irem H Ozbudak; Jeffrey R Galvin
Journal:  Radiographics       Date:  2007 May-Jun       Impact factor: 5.333

6.  Pulmonary capillary hemangiomatosis with severe pulmonary hypertension.

Authors:  Koji Ito; Toshihiro Ichiki; Keiji Ohi; Kensuke Egashira; Mituhiko Ohta; Kenichi Taguchi; Akira Takeshita
Journal:  Circ J       Date:  2003-09       Impact factor: 2.993

Review 7.  Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature.

Authors:  Pedro Almagro; Joaquim Julià; Maria Sanjaume; Guadalupe González; Jaume Casalots; José Luis Heredia; Jesús Martínez; Javier Garau
Journal:  Medicine (Baltimore)       Date:  2002-11       Impact factor: 1.889

8.  Capillary haemangiomatosis of the lungs.

Authors:  C A Wagenvoort; A Beetstra; J Spijker
Journal:  Histopathology       Date:  1978-11       Impact factor: 5.087

9.  Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline.

Authors:  Leo C Ginns; David H Roberts; Eugene J Mark; John L Brusch; Jennifer J Marler
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

Review 10.  Pulmonary capillary hemangiomatosis: a clinicopathologic review.

Authors:  M A Eltorky; A S Headley; H Winer-Muram; H E Garrett; J P Griffin
Journal:  Ann Thorac Surg       Date:  1994-03       Impact factor: 4.330

  10 in total
  2 in total

1.  Pulmonary capillary hemangiomatosis: the role of invasive cardiopulmonary exercise testing.

Authors:  Hilary M DuBrock; Richard L Kradin; Josanna M Rodriguez-Lopez; Richard N Channick
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

2.  Pulmonary Capillary Hemangiomatosis without Pulmonary Hypertension: An Early Stage of Disease?

Authors:  Wan-Jun Wang; Cheng Hong; Qian Han; Ying-Ying Gu; Nuo-Fu Zhang; Rong-Chang Chen; Shi-Yue Li; Nan-Shan Zhong; Chun-Li Liu
Journal:  Chin Med J (Engl)       Date:  2018-01-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.